Traditional MIC-based antibiotic susceptibility testing often misses sub-resistant bacteria, including persistent, tolerant, and heteroresistant populations, which may contribute to treatment failure and resistance evolution. Researchers at Huazhong University of Science and Technology have developed DP-AST, a deep learning-based microfluidic rapid phenotypic AST platform inspired by the Dujiangyan irrigation system. DP-AST measures MIC, bacterial growth activity, and concentration-effect curves to identify hidden sub-resistant bacteria. The study also identified gadE as a key regulator of amikacin sub-resistance in E. coli, offering new insights for resistance mechanism studies and future clinical diagnostics.Traditional MIC-based antibiotic susceptibility testing often misses sub-resistant bacteria, including persistent, tolerant, and heteroresistant populations, which may contribute to treatment failure and resistance evolution. Researchers at Huazhong University of Science and Technology have developed DP-AST, a deep learning-based microfluidic rapid phenotypic AST platform inspired by the Dujiangyan irrigation system. DP-AST measures MIC, bacterial growth activity, and concentration-effect curves to identify hidden sub-resistant bacteria. The study also identified gadE as a key regulator of amikacin sub-resistance in E. coli, offering new insights for resistance mechanism studies and future clinical diagnostics.Traditional MIC-based antibiotic susceptibility testing often misses sub-resistant bacteria, including persistent, tolerant, and heteroresistant populations, which may contribute to treatment failure and resistance evolution. Researchers at Huazhong University of Science and Technology have developed DP-AST, a deep learning-based microfluidic rapid phenotypic AST platform inspired by the Dujiangyan irrigation system. DP-AST measures MIC, bacterial growth activity, and concentration-effect curves to identify hidden sub-resistant bacteria. The study also identified gadE as a key regulator of amikacin sub-resistance in E. coli, offering new insights for resistance mechanism studies and future clinical diagnostics.

World Sepsis Day on 13 September 2026 / Critical care specialists Professor Jan Rossaint and Professor Alexander Zarbock from the University of Münster talk about the latest research being done on sepsis and other types of systemic inflammation / Examples include kidney damage after major surgery and the search for biomarkers that predict risks

Cambridge, Mass., September 3, 2026 — Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to broaden the exposure to “emerging technology trends, including opportunities across the AI value chain”, announced on 18 August 2026. All changes will be implemented after the market close on 11 September 2026 (Friday) and take effect on 14 September 2026 (Monday).